PMID- 10541378
OWN - NLM
STAT- MEDLINE
DCOM- 19991124
LR  - 20121115
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 5
IP  - 10 Suppl
DP  - 1999 Oct
TI  - Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and 
      (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with 
      relapsed, refractory non-Hodgkin's lymphoma.
PG  - 3292s-3303s
AB  - The pharmacokinetics, dosimetry, and immunogenicity of 131I- and 
      (111)In-/90Y-humanized LL2 (hLL2) anti-CD22 monoclonal antibodies were determined 
      in patients with recurrent non-Hodgkin's lymphoma. Fourteen patients received 
      tracer doses of 131I-hLL2 followed 1 week later by therapeutic doses intended to 
      deliver 50-100 cGy to the bone marrow. Another eight patients received 
      (111)In-hLL2 followed by therapy with 90Y-hLL2 also delivering 50 or 100 cGy to 
      the bone marrow. The blood T(1/2) (hours) for the tracer infusions of 131I-hLL2 
      was 44.2 +/- 10.9 (mean +/- SD) compared with 54.2 +/- 25.0 for the therapy 
      infusions, whereas the values were 70.7 +/- 17.6 for (111)In-hLL2 and 65.8 +/- 
      15.0 for 90Y-hLL2. The estimated average radiation dose from 131I-hLL2 in tumors 
      >3 cm was 2.4 +/- 1.9 cGy/mCi and was only 0.9-, 1.0-, 1.1-, and 1.0-fold that of 
      the bone marrow, lung, liver, and kidney, respectively. In contrast, the 
      estimated average radiation dose from 90Y-hLL2 in tumors >3 cm was 21.5 +/- 10.0 
      cGy/mCi and was 3.7-, 2.5-, 1.8-, and 2.5-fold that of the bone marrow, lung, 
      liver, and kidney, respectively. No evidence of significant anti-hLL2 antibodies 
      was seen in any of the patients. Myelosuppression was the only dose-limiting 
      toxicity and was greater in patients who had prior high-dose chemotherapy. 
      Objective tumor responses were seen in 2 of 13 and 2 of 7 patients given 
      131I-hLL2 or 90Y-hLL2, respectively. In conclusion, 90Y-hLL2 results in a more 
      favorable tumor dosimetry compared with 131I-hLL2. This finding, combined with 
      the initial anti-tumor effects observed, encourage further studies of this agent 
      in therapeutic trials.
FAU - Juweid, M E
AU  - Juweid ME
AD  - Garden State Cancer Center, Belleville, New Jersey 07109, USA. gscancer@att.net
FAU - Stadtmauer, E
AU  - Stadtmauer E
FAU - Hajjar, G
AU  - Hajjar G
FAU - Sharkey, R M
AU  - Sharkey RM
FAU - Suleiman, S
AU  - Suleiman S
FAU - Luger, S
AU  - Luger S
FAU - Swayne, L C
AU  - Swayne LC
FAU - Alavi, A
AU  - Alavi A
FAU - Goldenberg, D M
AU  - Goldenberg DM
LA  - eng
GR  - CA-39841/CA/NCI NIH HHS/United States
GR  - CA-67026/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, B-Lymphocyte)
RN  - 0 (CD22 protein, human)
RN  - 0 (Cd22 protein, mouse)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (Indium Radioisotopes)
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Lectins)
RN  - 0 (Sialic Acid Binding Ig-like Lectin 2)
RN  - 0 (Yttrium Radioisotopes)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Animals
MH  - Antibodies, Anti-Idiotypic/blood
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antigens, CD/*immunology
MH  - Antigens, Differentiation, B-Lymphocyte/*immunology
MH  - *Cell Adhesion Molecules
MH  - Female
MH  - Humans
MH  - Indium Radioisotopes/*therapeutic use
MH  - Iodine Radioisotopes/*therapeutic use
MH  - *Lectins
MH  - Lymphoma, Non-Hodgkin/*radiotherapy
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - *Radioimmunotherapy/adverse effects
MH  - *Radiotherapy Dosage
MH  - Recurrence
MH  - Sialic Acid Binding Ig-like Lectin 2
MH  - Yttrium Radioisotopes/*therapeutic use
EDAT- 1999/10/29 00:00
MHDA- 1999/10/29 00:01
CRDT- 1999/10/29 00:00
PHST- 1999/10/29 00:00 [pubmed]
PHST- 1999/10/29 00:01 [medline]
PHST- 1999/10/29 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1999 Oct;5(10 Suppl):3292s-3303s.